|
dostarlimab + chemotherapy |
placebo + chemotherapy |
---|---|---|
PFS dMMR/MSI-H population |
||
Number of patients evaluated |
|
|
HR (95% CI) |
|
|
P-value |
|
|
At 24 months (95% CI) |
|
|
PFS overall patient population |
||
Number of patients evaluated |
|
|
HR (95% CI) |
|
|
P-value |
|
|
At 24 months (95% CI) |
|
|
PFS MMRp/MSS populationa |
||
Number of patients evaluated |
|
|
HR (95% CI) |
|
|
P-value |
|
|
At 24 months (95% CI) |
|
|
OS overall patient populationb |
||
HR (95% CI) |
|
|
P-value |
|
|
At 24 months (95% CI) |
|
|
OS dMMR/MSI-H populationa,d |
||
HR (95% CI) |
|
|
P-value |
|
|
At 24 months (95% CI) |
|
|
OS MMRp/MSS populationa,e |
||
HR (95% CI) |
|
|
P-value |
|
|
At 24 months (95% CI) |
|
|